Invention Grant
US09346759B2 Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
有权
5-（2 - {[6-（2,2-二氟-2-苯基乙氧基）己基]氨基} -1-（R） - 羟基乙基）-8-羟基喹啉-2（1H） - 酮，heminapadisytlate 作为二肾上腺素能受体的激动剂
![Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor](/docs/US/2016-05-24/US09346759B2/abs.jpg.600x600.jpg)
- Patent Title: Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor
- Patent Title (中): 5-（2 - {[6-（2,2-二氟-2-苯基乙氧基）己基]氨基} -1-（R） - 羟基乙基）-8-羟基喹啉-2（1H） - 酮，heminapadisytlate 作为二肾上腺素能受体的激动剂
-
Application No.: US14386424Application Date: 2013-03-15
-
Publication No.: US09346759B2Publication Date: 2016-05-24
- Inventor: Gemma Amat Mestres , Elvira Balaguer Ardanuy , Francesc Carrera Carrera , Iolanda Marchueta Hereu , Enrique Moyes Valls
- Applicant: ALMIRALL, S.A.
- Applicant Address: ES Barcelona
- Assignee: Almirall, S.A.
- Current Assignee: Almirall, S.A.
- Current Assignee Address: ES Barcelona
- Agency: Finnegan, Henderson, Farabow Garrett & Dunner LLP
- Priority: EP12382101 20120320
- International Application: PCT/EP2013/055488 WO 20130315
- International Announcement: WO2013/139712 WO 20130926
- Main IPC: C07D215/227
- IPC: C07D215/227 ; C07D215/26 ; A61K31/4704 ; A61K45/06
![Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor](/abs-image/US/2016/05/24/US09346759B2/abs.jpg.150x150.jpg)
Abstract:
The present invention is directed to novel polymorphic crystal forms of a 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisylate. The invention is also directed to pharmaceutical compositions comprising said polymorphic crystal forms, methods of using them to treat respiratory diseases associated with β2 adrenergic receptor activity and a process for preparing such polymorphic crystal forms.
Public/Granted literature
Information query
